Dr. Mehdi Mollapour is a Professor, Vice Chair for Translational Research and Director of Renal Cancer Biology Program for the Department of Urology, and Adjunct Professor at the Department of Biochemistry and Molecular Biology at the State University of New York, Upstate Medical University.
After receiving his PhD in Biochemistry from the University College London (UCL), UK, Dr. Mollapour completed his post-doctoral research at the University of Sheffield, UK. He is also trained as a research fellow at the Urologic Oncology Branch, National Cancer Institute, NIH.
Dr. Mollapour previously received the Federation of European Societies (FEBS) fellowship and the First Ferruccio Ritossa Career Award from Cell Stress Society International. He was the Young Investigator of the Society for Basic Urological Research (SBUR) in 2017. Dr Mollapour is a Research Scholar of the Urology Care Foundation and the American Urological Association (AUA), as well as the Fellow of Cell Stress Society International.
Dr. Mollapour has published more than 80-scientific papers, reviews and book chapters. His scientific contributions include demonstrating the reciprocal regulation of the molecular chaperone Hsp90 and its kinase clients and how this translates towards tumors selectivity and sensitivity to Hsp90 drugs. This mechanism is also referred to as "the Chaperone Code". Dr Mollapour's research team funded by NIH, NCI and DoD work on clear cell renal Cell Carcinoma (ccRCC), Birt-Hogg-Dubé syndrome (BHD) and Tuberous Sclerosis Complex (TSC). His group has identified new Hsp90 co-chaperones, FNIP1/FNIP2 and Tsc1, which modulate Hsp90 chaperone activity. They are also evaluating the drugs that target the molecular chaperone complex in kidney, bladder and breast cancers.
Susan Kahn Photography